Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Confirmatory phase III study of PF-06438179 meets primary endpoint

Sep. 19, 2016

Phase II study of Flex Pharma's FLX-787 in ALS begins

Sep. 14, 2016

GlaxoSmithKline submits MAA for sirukumab in rheumatoid arthritis

Sep. 13, 2016

New approval for Bristol-Myers Squibb's Orencia in Europe

Sep. 7, 2016

Reata Pharmaceuticals presents nitric oxide production inhibitors

Sep. 7, 2016

FDA awards Santhera USD 246,000 for the development of omigapil

Sep. 1, 2016

MK-8449: a second generation SYK/ZAP70 inhibitor from Merck

Sep. 1, 2016

Facio establishes tool to aid in FSHD drug discovery

Sep. 1, 2016

FDA approves biosimilar etanercept Erelzi

Aug. 31, 2016

Eli Lilly begins phase II trial of LY-3337641 in patients with rheumatoid arthritis

Aug. 30, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...